Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Inlyta (axitinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

VEGFR inhibitor

Related drugs:

‹

›

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
PD-L1 expression	Clear Cell Renal Cell Carcinoma	PD-L1 expression	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: B - Late Trials avelumab + axitinib Sensitive : B	avelumab + axitinib Sensitive: B - Late Trials avelumab + axitinib Sensitive : B